Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Core Insights - Pfizer's experimental obesity drug demonstrated a weight loss of up to 12.3% in patients without diabetes during a mid-stage trial [1] Company Summary - The obesity drug was acquired through the Metsera deal, indicating Pfizer's strategic expansion into the obesity treatment market [1]